Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
life sciences
national blog main
san francisco blog main
blueprint medicines
cancer
cancer drugs
clinical trials
eli lilly
national top stories
roche
san francisco top stories
avapritinib
boston
deals
europe blog main
fda
genentech
investing
medullary thyroid cancer
non-small cell lung cancer
pralsetinib
selpercatinib
thyroid cancer
amgen
black diamond therapeutics
bladder cancer
capmatinib
cobimetinib
cstone pharmaceuticals
deciphera pharmaceuticals
endometral cancer
europe top stories
european medicines agency
european society for medical oncology
fisogatinib
flatiron health
gastrointestinal stromal tumors
What
cancer
4
×
drug
4
×
medicines
4
×
approval
blueprint
fda
ipo
research
ret
targets
address
approves
biotech
black
candidate
carries
certain
clinic
companies
currently
designed
despite
diamond
eluded
family
genetic
hardest
hit
hopes
hottest
hunters
latest
lead
leading
lines
marketing
molecular
muscle
nears
new
Language
unset
Current search:
drug
×
cancer
×
medicines
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic